On The Pen GLP-1 News

Chart trend

Position in the Medicine chart (US), last 90 days.

#1#47#92JunJulAugSep

#13

all-time peak

255

days in the top 50 since Nov 2024

Latest episodes

Showing 20 · updated from the feed

We’re Solving Obesity. Now Who Pays for It?

This week on On The Pen, the GLP-1 story is moving in two very different directions. The Fifth Circuit handed FDA major wins in the fight over semaglutide and tirzepatid

Sep 2
24 min

GLP-1 Coverage Is COLLAPSING in 2027

GLP-1 access is getting tighter just as obesity treatment is becoming more effective, more affordable, and more important to public health. In this episode of the On The

Aug 26
34 min

$50 Zepbound Incoming? China Has US in a GLP-1 “Chokehold”

Could GLP-1 medications eventually cost just $40 to $50 per month? Hims & Hers CEO Andrew Dudum thinks so, and if he’s right, it could completely change access to obesity

Aug 18
45 min

200 GLP-1 Deaths, Chrissy Metz & a Stunning Harvard Study

Https://www.otplinks.com Based on the transcript flow, here’s a clean YouTube description with chapter timestamps. The transcript itself doesn’t include timecodes, so th

Aug 12
31 min

Eli Lilly Earnings Call Recap: Retatrutide News

https://www.otplinks.com

Aug 7
59 min

Novo Nordisk Warned us For Years About Synthesized Semaglutide. Now They Want In.

Novo Nordisk has spent years warning patients, regulators, lawmakers, and courts about the risks of synthetic semaglutide. Now, as patents begin to expire and China’s pha

Aug 4
18 min

Retatrutide Biologic Battle: The Story Gets Bigger

https://www.otplinks.comhttps://www.voafit.com/otpEpisode Referenced: https://www.youtube.com/watch?v=K8kaSoFCZ0c&t=41sThe retatrutide biologic fight is bigger than folks

Jul 28
20 min

GLP-1 Showdown: Inside The High Stakes War over Patients

Novo Nordisk just declared legal war on Eli Lilly as the battle over GLP-1 patients intensifies. But just because patients are being fought over does not mean they are be

Jul 22
27 min

Medicare, New Drugs, and a Surprising GLP-1 Trend, What Patients Need to Know

What happens when patients stop taking a GLP-1? New real-world data reveals that more than half eventually come back, and it may completely change the way we think about

Jul 14
31 min

Compound GLP-1 Poll STUNS THE INTERNET!

What If We've Been Asking the Wrong Question?Patients say compounded GLP-1s are more effective than branded medications. Dave explains why the answer may have nothing to

Jul 8
15 min

How To Get $50 GLP-1

Millions of Medicare beneficiaries are about to gain access to GLP-1 weight loss medications for as little as $50 per month through the new Medicare Bridge Program, launc

Jun 23
44 min

What Comes After Zepbound? The Biggest ADA 2026 Obesity Drug Breakthroughs

ADA 2026 delivered a massive wave of obesity and diabetes data, and in this episode of On The Pen, Dave Knapp (@manonthemounjaro) sits down with Jen (@JcanNuSH) ⁠ to bre

Jun 16
1 h 15 min

Retatrutide Just Reached Bariatric Surgery Results

Dave sits down with nurse practitioner and former Retatrutide clinical trial participant David White to break down the biggest obesity headlines from the 2026 American Di

Jun 11
48 min

Retatrutide Before FDA Approval? Lilly Just Changed the Conversation

Dave breaks down an unreported Expanded Access Pathway that Eli Lilly has quietly established for Retatrutide.

Jun 9
20 min

Eli Lilly Isn’t Telling Us About Their Future Obesity Drugs

Does Eli Lilly already have the solve for obesity? In this episode of On the Pen — the Weekly Dose Podcast, host Dave Knapp breaks down a stunning comment from Lilly's Ch

Jun 2
20 min

Retatrutide, Multi Agonist Obesity Drugs, and the PBM Access War

https://linktr.ee/manonthemounjaro

May 26
30 min

Lilly Bets $8B on Weight Loss Future

https://linktr.ee/manonthemounjaro

May 19
23 min

The Next Two Weeks in GLP1 Are Huge, Here's Why

http://www.otplinks.com

May 12
1 h 07 min

He Took Retatrutide 40mg and Proved a Point

This episode examines a serious case involving retatrutide, where an individual experienced an overdose due to improper medication administration. We discuss the critical

May 5
36 min

Eli Lilly Earnings Call Recap: Q1 2026

We just got done listening to the quarter one, 2026 Eli Lilly earnings call. There was a lot of information to get into, whether you're interested in retatrutide, elorali

Apr 30
25 min

Chart positions

Where On The Pen GLP-1 News ranks today in each Apple Podcasts chart (US, Sep 6, 2026).

#71 ▼ 9 Medicine US

What listeners say

A curated, balanced selection of Apple Podcasts reviews.

Dave Knapp has had a profound impact on so many people, and his podcast is proof of why. Every episode is packed with clear, informative, and genuinely helpful guidance. Dave has a rare ability to take complex topics and break them down in a way that’s easy to understand, relatable, and actionable. Whether he’s diving into health, mindset, or personal transformation, you can feel his passion and authenticity in every word. It’s obvious he truly wants people to win — and it shows through the value he delivers week after week. If you’re looking for a podcast that will educate you, challenge you, and inspire you to level up your life, Dave’s is absolutely the one. Highly recommend.

Jacklemay · Nov 2025

I didn’t want to delete my earlier review, and the app won’t let me do another, so… here is an update. Although there is certainly less information about GLP-1s circulating these days, Dave has done a great job of building a news network that provides timely, relevant information about all things related to the disease of obesity and treatment options. While many of us are in maintenance and not as excited these days due to life’s pressures or whatever, Dave continues to peak our interests and provide what we need and want. For those non responders and slow responders, he provides a true Beacon of hope with quality, factual information that is fully vetted. I hope my life calms back down someday, so I can get more excited as well. Until then, Dave helps keep my toes in the water. All of Dave’s endeavors are worth a listen or watch. Not only does he do his best to provide timely and accurate information, but he also understands the fluid nature of the reported information in the frontier / Wild West era of incretins / GLP-1 s. He always strives to keep us updated and to make it fun for us. I especially appreciate having additional content from Dave that is a bit shorter. Don’t get me wrong! I want content of all lengths, but where I might want a longer video while I am doing my physical therapy or mandated walking, sometimes, I want something shorter and in audio form while I wait for a doctor’s appt or make a quick trip to Walgreens! Man, does this fill the bill! Thanks Dave for all you do! Also, thanks for keeping it clean. Some of my other favs drop a few too many f-bombs for my taste, which is none.

mhessacp · Nov 2025

This is my go to podcast for all things zepbound related. Dave gets the news out timely, leaves no stone uncovered, and his passion shines through. Great podcast!

The Conditts · Nov 2025

On the Pen with Dave Knapp is tops on up-to-date sources of legislation, insurance issues, latest medical advancements, and helpful hints for anyone on a glp1 medication (and even their loved ones). I highly recommend this podcast!

Debbie Musielak · Oct 2025

We strive to present a balanced view by showing a diverse range of reviews from Apple Podcasts.